Literature DB >> 18074356

Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice.

Guoyang Liao1, Yue Wang, Jinhai Chang, Tao Bian, Wenjie Tan, Mingbo Sun, Weidong Li, Huijuan Yang, Junying Chen, Xinwen Zhang, Shengli Bi, Masao Omata, Shude Jiang.   

Abstract

UNLABELLED: DNA immunization has been used to induce either humoral or cellular immune responses against many antigens, including hepatitis C virus (HCV). In addition, DNA immunizations can be enhanced or modulated at the nucleotide level. Genetic immunizations were examined in BALB/c mice through the use of plasmids and chimeric DNA constructs encoding HCV core proteins and hepatitis B virus (HBV) precore (preC) regions. Plasmids encoding the truncated HCV core induced potent humoral and cellular responses to HCV; pcDNA3.0A-C154 produced a stronger antibody response than pcDNA3.0A-C191 (P < 0.01) and pcDNA3.0A-C69 (P < 0.05). HBV preC enhanced the humoral and cellular immune responses of BALB/c mice to HCV; however, pcDNA3.0A-C69preC resulted in a weak cytotoxic T lymphocyte (CTL) response. In addition, the humoral and cellular immune responses to HCV of groups immunized with pcDNA3.0A-C154preC and pcDNA3.0A-C191preC plasmids were higher than those of groups immunized with pcDNA3.0A-C154 and pcDNA3.0A-C191. In vivo CTL responses verified that mice immunized with preC core fused DNAs showed significantly high specific lysis compared with mice immunized with HCV cores only (P < 0.01). In our study, pcDNA3.0A-C154preC led to the highest immune response among all DNA constructs.
CONCLUSION: DNA that encodes truncated HCV core proteins may lead to increased immune responses in vivo, and these responses may be enhanced by HBV preC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18074356     DOI: 10.1002/hep.21992

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice.

Authors:  Wenbo Zhu; Yanzi Chang; Chunchen Wu; Qingxia Han; Rongjuan Pei; Mengji Lu; Xinwen Chen
Journal:  Clin Vaccine Immunol       Date:  2010-06-02

2.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

3.  Prevalence of hepatitis C infection among intravenous drug users in Shanghai.

Authors:  Yan-Lin Tao; Yu-Fan Tang; Jian-Ping Qiu; Xiao-Feng Cai; Xiao-Ting Shen; Ya-Xin Wang; Xue-Tao Zhao
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

4.  Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.

Authors:  Wenbo Zhu; Chunchen Wu; Wanyu Deng; Rongjun Pei; Yun Wang; Liang Cao; Bo Qin; Mengji Lu; Xinwen Chen
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

5.  Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice.

Authors:  Maryam Yazdanian; Arash Memarnejadian; Mehdi Mahdavi; Fatemeh Motevalli; Seyed Mehdi Sadat; Rouhollah Vahabpour; Hossein Khanahmad; Hoorieh Soleimanjahi; Agata Budkowska; Farzin Roohvand
Journal:  Adv Biomed Res       Date:  2015-01-06

6.  The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response.

Authors:  Juris Jansons; Irina Sominskaya; Natalia Petrakova; Elizaveta S Starodubova; Olga A Smirnova; Ekaterina Alekseeva; Ruta Bruvere; Olesja Eliseeva; Dace Skrastina; Elena Kashuba; Marija Mihailova; Sergey N Kochetkov; Alexander V Ivanov; Maria G Isaguliants
Journal:  Cells       Date:  2019-02-28       Impact factor: 6.600

7.  General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007.

Authors:  Jian Lu; Yongdong Zhou; Xiaojing Lin; Yongzhen Jiang; Ruiguang Tian; Yonghui Zhang; Jia Wu; Fengwei Zhang; Yong Zhang; Yue Wang; Shengli Bi
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

8.  Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer.

Authors:  Maryam Yazdanian; Arash Memarnejadian; Mehdi Mahdavi; Seyed Mehdi Sadat; Fatemeh Motevali; Rouhollah Vahabpour; Hossein Khanahmad; Seyed Davar Siadat; Mohammad Reza Aghasadeghi; Farzin Roohvand
Journal:  Hepat Mon       Date:  2013-10-23       Impact factor: 0.660

9.  Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization.

Authors:  Christine Hartoonian; Zargham Sepehrizadeh; Mojtaba Tabatabai Yazdi; Yong Suk Jang; Lida Langroudi; Parisa Amir Kalvanagh; Babak Negahdari; Ali Karami; Massoumeh Ebtekar; Kayhan Azadmanesh
Journal:  Hepat Mon       Date:  2014-03-01       Impact factor: 0.660

10.  A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice.

Authors:  Yao Deng; Ke Zhang; Wenjie Tan; Yue Wang; Hong Chen; Xiaobing Wu; Li Ruan
Journal:  Vaccine       Date:  2009-02-12       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.